Antipsychotic long-acting injections improve relapse prevention in psychotic disorders. Three new risperidone formulations have been developed that offer advantages over currently available risperidone-based long-acting injections. Risperidone ISM^® is a monthly intramuscular injection that does not require loading doses or concurrent oral risperidone. RBP-7000 is a monthly subcutaneous injection not requiring loading or oral supplementation. BB0817 is a 6-monthly implant of risperidone injected subcutaneously. All three preparations have been shown to be effective and well tolerated in clinical trials. A fourth formulation (TV-46000), which can be given subcutaneously every 1 or 2 months, has recently begun trials.

抗精神病药长效注射剂可改善精神病的复发预防。已开发出三种新的利培酮制剂，与目前可用的基于利培酮的长效注射剂相比具有优势。利培酮 ISM ^®是每月一次的肌肉注射，不需要负荷剂量或同时口服利培酮。RBP-7000 是每月一次皮下注射，不需要负荷或口服补充剂。BB0817 是一种为期 6 个月的利培酮皮下注射植入物。在临床试验中，所有三种制剂均已证明有效且耐受性良好。最近开始试验第四种制剂 (TV-46000)，可以每 1 或 2 个月皮下注射一次。